Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Jessica T. Leonard, Amrita Desai, Peter Ferreira-Gandolfo, Denise Lackey, Kevin Christmas, Richard T Maziarz, Eneida R Nemecek

Blood (2023) 142 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2023-177864

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Journal Articles

Thromboprophylaxis with Intermediate Dose Low Molecular Weight Heparin in Adults Undergoing Induction with L-Asparaginase for Acute Lymphoblastic Leukemia

Hong De Sa, Thomas G Deloughery, Curtis A Lachowiez, Jessica T. Leonard, Sven R. Olson, Joseph J. Shatzel, Ronan T. Swords, Elie Traer, Brandon Hayes-Lattin

Blood (2023) 142 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2023-178918

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Arthur Nguyen, Joseph S Bubalo, Jennifer N. Saultz, Brandon Hayes-Lattin, Andy Chen, Rachel J. Cook, Arpita Gandhi, Jessica Leonard, Richard T. Maziarz, Yazan Migdady, Eneida R. Nemecek, Levanto Schachter

Blood (2022) 140 (Supplement 1): 12856–12858.

https://doi.org/10.1182/blood-2022-156011

Published: 2022

Journal Articles

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Emily C. Liang, Simone E. Dekker, Jean M.G. Sabile, Stefan Torelli, Amy Zhang, Katharine Miller, Parveen Shiraz, Brandon Hayes-Lattin, Jessica Leonard, Lori Muffly

Blood (2022) 140 (Supplement 1): 1732–1733.

https://doi.org/10.1182/blood-2022-157442

Published: 2022

Journal Articles

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood (2022) 139 (26): 3722–3731.

https://doi.org/10.1182/blood.2021014497

Published: 2022

Includes: Supplemental data

Journal Articles

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph + ALL

Jessica T. Leonard, Yoko Kosaka, Pavani Malla, Dorian LaTocha, Adam Lamble, Brandon Hayes-Lattin, Kaelan Byrd, Brian J. Druker, Jeffrey W. Tyner, Bill H. Chang, Evan Lind

Blood (2021) 137 (7): 939–944.

https://doi.org/10.1182/blood.2020005655

Published: 2021

Journal Articles

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Pavani Malla, MS, Brandon Hayes-Lattin, MD, Adam J. Lamble, MD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 2694.

https://doi.org/10.1182/blood-2018-99-119301

Published: 2018

Journal Articles

Thromboprophylaxis with Fixed Dose, 1mg/Kg/Day, Low Molecular Weight Heparin in Adults Undergoing Induction with Asparaginase for Acute Lymphoblastic Leukemia. Results of a Single Institution Cohort Study

Luai S Al Rabadi, MD, Sven Reid Olson, MD, Joseph J. Shatzel, MD, Thomas G. Deloughery, MD MACP, FAWM, Brandon Hayes-Lattin, MD

Blood (2017) 130 (Supplement 1): 2397.

https://doi.org/10.1182/blood.V130.Suppl_1.2397.2397

Published: 2017

Journal Articles

Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia

Jessica T Leonard, MD, Bill H. Chang, MD PhD, Jeffrey W. Tyner, PhD, Brandon Hayes-Lattin, MD, Marc M. Loriaux, Brian J. Druker, Uma Borate, MD

Blood (2016) 128 (22): 2811.

https://doi.org/10.1182/blood.V128.22.2811.2811

Published: 2016

Journal Articles

Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)

Jessica Leonard, MD, Joelle Rowley, Brandon Hayes-Lattin, MD, Jeffrey W. Tyner, PhD, Marc Loriaux, MD PhD, Brian J. Druker, MD, Bill H Chang, MD PhD

Blood (2015) 126 (23): 1329.

https://doi.org/10.1182/blood.V126.23.1329.1329

Published: 2015

Journal Articles

Improved Outcome with Busulfan, Melphalan, and Thiotepa Conditioning (BuMelTt) in Autologous Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

Tarunpreet Bains, MD, Andy I Chen, MD, PhD, Andrew Lemieux, BS, Brandon Hayes-Lattin, MD, Jose F. Leis, MD, PhD, Richard T Maziarz, MD

Blood (2011) 118 (21): 3110.

https://doi.org/10.1182/blood.V118.21.3110.3110

Published: 2011

Journal Articles

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

Amin M. Alousi, Daniel J. Weisdorf, Brent R. Logan, Javier Bolaños-Meade, Shelly Carter, Nancy DiFronzo, Marcelo Pasquini, Steven C. Goldstein, Vincent T. Ho, Brandon Hayes-Lattin, John R. Wingard, Mary M. Horowitz, John E. Levine

Blood (2009) 114 (3): 511–517.

https://doi.org/10.1182/blood-2009-03-212290

Published: 2009

Journal Articles

BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD)

Amin Alousi, MD, Daniel J. Weisdorf, MD, Brent R. Logan, PhD, Javier Bolanos-Meade, MD, Steven C. Goldstein, MD, Vincent T Ho, MD, Brandon Hayes-Lattin, MD, John R. Wingard, MD, Mary M. Horowitz, MD, MS, John E. Levine, MD, MS

Blood (2008) 112 (11): 55.

https://doi.org/10.1182/blood.V112.11.55.55

Published: 2008

Journal Articles

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Tibor Kovacsovics, Byung Park, Brandon Hayes-Lattin, Jose F. Leis, Peter T. Curtin, Gabrielle Meyers, Elliot Epner, Richard T. Maziarz

Blood (2007) 110 (11): 1988.

https://doi.org/10.1182/blood.V110.11.1988.1988

Published: 2007

Journal Articles

Rescue from Failed Growth Factor and/or Chemotherapy HSC Mobilization with G-CSF and AMD3100: An Institutional Experience.

Richard Thomas Maziarz, MD, Adam Dunn, BS, Lisa Hansen, RN, Keith Hansen, MD, Jose F. Leis, MD, PhD, Brandon Hayes-Lattin, MD, Tibor Kovacsovics, MD, Gary Calandra, MD, Cedar Fowler, BA

Blood (2006) 108 (11): 5460.

https://doi.org/10.1182/blood.V108.11.5460.5460

Published: 2006

Journal Articles

Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.

Brandon Hayes-Lattin, MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Koen van Besien, MD, Julie M. Vose, MD, Hillard M. Lazarus, MD, J. Douglas Rizzo, MD, MS, Parameswaran Hari, MD

Blood (2006) 108 (11): 3021.

https://doi.org/10.1182/blood.V108.11.3021.3021

Published: 2006

NARROW

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Thromboprophylaxis with Intermediate Dose Low Molecular Weight Heparin in Adults Undergoing Induction with L-Asparaginase for Acute Lymphoblastic Leukemia

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph + ALL

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Thromboprophylaxis with Fixed Dose, 1mg/Kg/Day, Low Molecular Weight Heparin in Adults Undergoing Induction with Asparaginase for Acute Lymphoblastic Leukemia. Results of a Single Institution Cohort Study

Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia

Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)

Improved Outcome with Busulfan, Melphalan, and Thiotepa Conditioning (BuMelTt) in Autologous Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD)

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Rescue from Failed Growth Factor and/or Chemotherapy HSC Mobilization with G-CSF and AMD3100: An Institutional Experience.

Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only